GLP-1 prescription growth reflects FDA approvals of newer, more effective agents like semaglutide and tirzepatide, demonstrated cardiovascular benefits in clinical trials, and expanded indications for both type 2 diabetes and chronic weight management
The D- form is completely inactive and in large quantities and particular conditions, the D- form may inhibit the utilization of L-carnitine
Ongoing research is needed before any clinical conclusions can be drawn
In a twist, the study found that although there was a small increase in diabetic retinopathy, GLP-1 use appeared to protect against the conditions progression and sight-threatening complications
Eric De Jonge, director of geriatrics at MedStar Washington Hospital Center in Washington, D.C
Mistake 2: skipping resistance training Many people view GLP-1 therapy as a weight loss solution and assume that the medication does all the work